This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ntais, C. Articles by Ioannidis, J. P. A. Search for Related Content PubMed PubMed Citation Articles by Ntais, C. Articles by Ioannidis, J. P. A.

SRD5A2 Gene Polymorphisms and the Risk of Prostate Cancer

A Meta-Analysis

Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina 45110, Greece [C. N., A. P., J. P. A. I.]; Biomedical Research Institute, Foundation for Research and Technology–Hellas, Ioannina 45110, Greece [J. P. A. I.]; and Division of Clinical Care Research, Department of Medicine, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111 [J. P. A. I.]

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Several polymorphisms in the 5-reductase type 2 (SRD5A2) gene have been implicated as risk factors for prostate cancer. We performed a meta-analysis of 9 studies (12 comparisons) with V89L genotyping (2558 prostate cancer cases and 3349 controls), 7 studies (8 comparisons) with A49T genotyping (1594 cases and 2137 controls), and 4 studies with TA repeat genotyping (1109 cases and 1378 controls). The random effects odds ratio (OR) for the L versus V allele was 1.02 [95% confidence interval (CI), 0.94–1.11]. There was no suggestion of an overall effect either in recessive or dominant modeling, and comparison of L/L versus V/V also showed no differential prostate cancer susceptibility (OR, 1.03; 95% CI, 0.83–1.28). The random effects OR for the T versus A allele was 1.56 (95% CI, 0.93–2.62). However, excluding the first published study there was no evidence for any effect (OR, 1.08; 95% CI, 0.72–1.61). Moreover, the T allele had a low prevalence (0%, 1%, and 2% in Asian, African and European controls, respectively). The random effects OR for longer versus short TA alleles was 0.88 (95% CI, 0.74–1.05). Longer TA allele homozygotes were nonsignificantly under-represented among prostate cancer cases (OR, 0.53; 95% CI, 0.26–1.06). We exclude a role for the V89L polymorphism in conferring susceptibility to prostate cancer. The A49T and TA repeat polymorphisms may have a modest effect on prostate cancer susceptibility, but bias and chance findings cannot be excluded; any genuine genetic effects would account only for a small proportion of prostate cancer in the population.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
High levels of endogenous androgens have long been considered as risk factors for prostate cancer (1 , 2) . Therefore, it has been postulated that variants in the genes of the enzymes involved in androgen biosynthesis and metabolism may be associated with the development of prostate cancer. Among these genes, SRD5A2 is located on chromosome 2 and encodes the steroid 5-reductase type 2 enzyme expressed primarily in the androgen-sensitive cells of genital skin and the prostate gland (3 , 4) . This enzyme irreversibly converts testosterone into the main prostatic androgen, DHT.² The binding affinity to the prostatic androgen receptor of DHT is five times higher than that of testosterone (5) . Ross et al. (6) demonstrated that young Japanese men have lower 5-reductase activity than young Caucasian-American and African-American men. Similarly, Wu et al. (7) reported that the DHT:testosterone ratio was highest in African-Americans, intermediate in Caucasians, and lowest in Asian-Americans, corresponding to the respective risk of developing prostate cancer in these groups.

Certain SRD5A2 polymorphisms may encode for 5-reductase enzyme variants with different activities, probably because of altered mRNA stability (8) . Makridakis et al. (9) reported a missense substitution in the SRD5A2 gene, which replaces valine at codon 89 with leucine (V89L). This substitution is associated with a reduced 5-reductase activity both in vitro and in vivo (9) . In another variant of the SRD5A2 gene (10) , an alanine residue at codon 49 is replaced with threonine (A49T). This missense mutation increases steroid 5-reductase activity 5-fold in vitro (10) . Thus, these polymorphisms might alter DHT levels and consequently the risk of prostate cancer. A polymorphism in the 3' untranslated region has also been reported, with different numbers of TA dinucleotide repeats (11) .

Molecular epidemiological studies have presented seemingly contradictory results concerning a potential role of the V89L (12, 13, 14, 15, 16, 17, 18, 19, 20) , A49T (10 , 16, 17, 18, 19, 20, 21) , and TA repeat (17 , 18 , 20 , 22) polymorphisms in prostate cancer susceptibility. Single studies may have been underpowered to detect dose-response relationships or even overall effects. Given the amount of accumulated data, a quantitative synthesis of the evidence was deemed important to perform. In this meta-analysis we aimed to obtain summary estimates for the strength of the postulated genetic association, as well as to quantify and explain the potential between-study heterogeneity.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Identification and Eligibility of Relevant Studies.
We considered all of the studies that examined the association of the V89L, A49T, and TA repeat polymorphisms with prostate cancer. Sources included MEDLINE and EMBASE (last search update January, 2003). The search strategy was based on combinations of "prostate cancer," "SRD5A2," "androgens," "polymorphism," "allele," and "genetics." References of retrieved articles were also screened.

Nonfamilial case-control studies were eligible if they had determined the distribution of genotypes for any of the three polymorphisms in prostate cancer cases and in a concurrent control group of prostate cancer-free subjects using a molecular method for genotyping. We accepted disease-free controls regardless of whether they had BPH or not. Cases with prostate cancer were eligible regardless of whether they had a first-degree relative with prostate cancer or not. However, we excluded family-based studies of pedigrees with several affected cases per family, because their analysis is different (based on linkage considerations).

Data Extraction.
Two investigators independently extracted data and reached consensus on all of the items. The following information was sought from each report: authors, journal and year of publication, country of origin, selection and characteristics of prostate cancer cases and controls, demographics, racial descent of the study population (categorized as European, African, and Asian descent), eligible and genotyped cases and controls, and number of cases and controls for each SRD5A2 genotype. For studies including subjects of different racial descent, data were extracted separately for each race, whenever possible. Furthermore, we examined whether matching had been used, whether there was specific mention of blinding of the personnel who performed the genotyping to the clinical status of the subjects, and whether the genotyping method had been validated. Whenever key information was missing in a published report, we obtained the pertinent data directly from primary study investigators.

Meta-Analysis.
The primary analysis for the V89L polymorphism compared prostate cancer patients against controls for the contrast of L versus V alleles. This analysis aims to detect overall differences. We also examined the contrast of homozygotes (L/L versus V/V). Finally, we examined the contrast of L/L versus (V/L+V/V) and (V/L+L/L) versus V/V. These contrasts correspond to recessive and dominant effects, respectively, of the L allele. Similar contrasts were analyzed for the A49T polymorphism. For the TA repeat polymorphism, we contrasted the longer alleles [TA(9) and the very rare TA(18) combined] versus the short allele TA(0), as originally proposed (22) . Genotype contrasts used the same longer versus short allele classification.

Because case-control studies were involved, the OR was used as the metric of choice. Studies with subjects of different races were split into separate race-specific comparisons. For each genetic contrast, we estimated the between-study heterogeneity across all of the eligible comparisons using the ²-based Q statistic (23) . Heterogeneity was considered significant for P < 0.10. Data were combined using both fixed effects (Mantel-Haenszel) and random effects (DerSimonian and Laird) models (23) . Random effects incorporate an estimate of the between-study variance and provide wider CIs, when the results of the constituent studies differ among themselves. Random effects are more appropriate when heterogeneity is present (23) . Subgroup analyses estimated race-specific ORs for each allele contrast.

We also performed cumulative meta-analysis (24) and recursive cumulative meta-analysis (25 , 26) to evaluate whether the summary OR for the allele contrasts changed over time as more data accumulated. Inverted funnel plots and the Begg-Mazumdar publication bias diagnostic (nonparametric correlation coefficient; Ref. 27 ) evaluated whether the magnitude of the observed association was related to the variance of each study. Finally, we evaluated whether the summary results were different when the analyses were limited to studies with rigorous selection of cases and controls (those that confirmed histologically all of the prostate cancer cases and specifically screened all of the controls to rule out prostate cancer).

Analyses were conducted in SPSS 11.0 (SPSS, Inc., Chicago, IL), StatXact (Cytel Inc., Boston, MA), and Meta-Analyst (Joseph Lau, Boston, MA). All of the P values are two-tailed.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Eligible Studies
We identified 12 eligible reports (Refs. 10 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 ; Table 1 ), 2 of which (13 , 22) were derived from the same cohort, but presented complementary data on different polymorphisms. The number of studies with V89L (12, 13, 14, 15, 16, 17, 18, 19, 20) , A49T (10 , 16, 17, 18, 19, 20, 21) , and TA repeat data (16 , 17 , 19 , 22) was 9, 7, and 4, respectively. After splitting data per racial descent in 3 studies (10 , 14 , 15) , there were 12, 8, and 4 available comparisons for the three polymorphisms, respectively. There was a considerable diversity of ethnic groups.

With one exception (10) where the mean age of controls and cases differed by 5 years, the reported mean or median age of cases and controls was very similar (difference 2 years) and specific matching for age was described in 6 studies (13 , 16, 17, 18, 19 , 22) . Six reports (10 , 12, 13, 14 , 18 , 22) mentioned specifically blinding of the personnel who performed the genotyping. Appropriate molecular methods for genotyping were used. All of the studies used PCR. Some studies performed in addition sequencing (13 , 17 , 22) , single-strand conformational polymorphism analysis (10 , 18 , 20) , or ASO-hybridization and sequencing (21) . The distribution of genotypes in control groups was consistent with Hardy-Weinberg equilibrium for all three of the polymorphisms in all of the studies.

Meta-Analyses Databases (Table 2)
V89L.
The eligible studies included 2662 patients with prostate cancer and 3573 controls of whom 2558 and 3349, respectively, had genotype data. The L allele was more highly represented among controls of Asian descent (50%; 95% CI, 48–52) than in controls of European descent (31%; 95% CI, 30–32) or African descent (25%; 95% CI, 22–28). Overall, the prevalence of L/L homozygosity was 25%, 10%, and 5% in control subjects of Asian, European, and African descent, respectively. The respective prevalence rates of V/L heterozygosity were 49%, 42%, and 39%.

TA Repeats.
The eligible studies included 1192 patients with prostate cancer and 1574 controls of whom 1109 and 1378, respectively, had genotype data. The prevalence of longer TA repeat alleles was 14% (95% CI, 12–15) and 9% (95% CI, 7–12) in control subjects of European and Asian descent, respectively. Overall the prevalence of homozygosity for longer TA repeat alleles was 2.3% and 0.7%, in the two groups, respectively. No study included African descent subjects.

Quantitative Synthesis (Table 3)
V89L.
There was no evidence that the L allele modified the risk of prostate cancer (Fig. 1) . The summary OR was 1.02 by both random (P = 0.61) and fixed effects (P = 0.64). In subgroup analyses, no differences were observed in allele distribution between prostate cancer patients and controls of European, Asian, and African descent. We found no evidence of an association of the L/L genotype with the risk of prostate cancer relative to the V/V genotype. The 95% CIs excluded a large effect. No susceptibility effect was seen in either recessive or dominant models. There was no between-study heterogeneity in any of these analyses.

View larger version (19K): [in this window] [in a new window]   Fig. 1. Effect of the L versus V allele on the risk of prostate cancer. Each comparison is presented by the name of the first author, and the year of publication. Af signifies subjects of African descent, As signifies subjects of Asian descent. For each comparison, the point estimate of the OR and the accompanying 95% CI are shown. Also shown is the summary random effects estimate for the comparison along with the respective 95% CI. Values 1 denote an increased risk for prostate cancer with the L allele.

View larger version (15K): [in this window] [in a new window]   Fig. 2. Effect of the T versus A allele on the risk of prostate cancer. Values 1 denote an increased risk for prostate cancer with the T allele. Otherwise, figure set-up as per Fig. 1 .

View larger version (11K): [in this window] [in a new window]   Fig. 3. Effect of the longer TA alleles versus short TA allele on the risk of prostate cancer. Values 1 denote an increased risk for prostate cancer with the longer TA alleles. Otherwise, figure set-up as per Fig. 1 .

A49T.
The magnitude of the summary OR had not been stable, and it had changed considerably in the last 2 years with an apparent dissipation of the postulated effect (by random effects, summary OR for T versus A: 2.67 at the end of 1999, 2.74 at the end of 2000, 1.66 at the end of 2001, and 1.56 at the end of 2002). Excluding the first study in the field (10) that may be considered to provide the hypothesis-generating data, the remaining studies did not suggest any strong association between the T allele and prostate cancer (random effects OR, 1.08; 95% CI, 0.72–1.61; P = 0.70). The larger estimate of the association belonged to the smallest study, whereas the largest study had shown absolutely no effect. Analyses limited to studies with rigorous selection of cases and controls yielded similar results [2 studies (1200 alleles), OR 1.63 (95% CI, 0.26–10.2), no significant between-study heterogeneity].

TA Repeats.
Data were very limited to apply meaningfully recursive cumulative meta-analysis and publication bias diagnostics. Analyses limited to studies with rigorous selection of cases and controls yielded similar results [3 studies (2190 alleles), OR 0.85 (95% CI, 0.64–1.12), no significant between-study heterogeneity].

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
This meta-analysis examined three well-characterized polymorphisms of the SRD5A2 gene in their relationship to prostate cancer susceptibility. The current evidence definitively excludes any increased risk conferred by the V89L polymorphism. No additional studies are needed on this postulated association. One cannot exclude that the T allele in the A49T polymorphism may increase modestly the risk for prostate cancer, and homozygosity for the longer TA repeat alleles may decrease modestly this risk. Given the relative rarity of these two variants on a population basis, larger studies with many thousands of subjects would be needed to verify such effects. However, the meta-analysis clearly demonstrates that the contribution of these polymorphisms to prostate cancer at a population level is probably small, if at all present. Thus very large studies, if ever conducted, should be carefully designed to avoid dilution of the observed effects, and the cost of running such studies should be carefully weighted against the anticipated small gain of information. For A49T, the attributable fraction of prostate cancer in subjects of European descent is probably 1%, whereas the polymorphism is completely absent in subjects of Asian descent. Even the observed effect may be spurious, because it was largely driven by the first reported study in the field, i.e., from data that are mostly hypothesis-generating. Longer TA repeat homozygosity also occurs in only 2.3% of European descent subjects, and <1% of Asian subjects. No data have been generated on the association of this polymorphism with prostate cancer on African subjects, where the prevalence of longer TA repeat alleles may be higher (8) .

The meta-analysis did not address whether these three polymorphisms may have an effect on the clinical behavior of prostate cancer or other clinicopathological attributes. A few studies have generated some relevant data, but their results have been contradictory. Nam et al. (12) claimed a 3.3-fold significantly increased risk of disease recurrence with the V/V and V/L genotypes. Conversely, Soderstrom et al. (19) claimed a significant 5.7-fold increased risk of metastatic disease with the L/L genotype, and Shibata et al. (28) also claimed a shorter time to biochemical failure for L/L subjects. Two other studies (17 , 29) found no significant associations for the V89L polymorphism with clinicopathological correlates despite adequate sample sizes. Jaffe et al. (29) claimed that the T allele of the A49T polymorphism is associated with characteristics suggesting poor prognosis, and a younger age at diagnosis and a trend for more advanced stage were claimed by Soderstrom et al. (19) , but no such associations were seen in 2 other studies (17 , 21) . Longer TA repeat homozygosity associations with stage have been probed on very limited data (17 , 22) . Definitions of clinicopathological correlates varied considerably across these studies, thus making difficult the comparison of their results. Given the multiplicity of possible comparisons and the unavoidable flexibility of choosing and defining these correlates, associations may have been detected by chance alone. The differences between studies are consistent with spurious findings, although some genuine association cannot be totally excluded.

The SRD5A2 gene may also have other polymorphisms that were not considered in the meta-analysis. One of them, the R227Q polymorphism, is already known, but is very rare: Q heterozygotes have a prevalence of only 0.2% in Asian descent subjects where this polymorphism has been studied (18) . Nevertheless, we should note that linkage studies (30, 31, 32) based on genome scans have not identified overall any significant linkage of prostate cancer with the region of 2p23, the chromosomal location of the SRD5A2 gene.

The biochemical evidence for a putative relationship of SRD5A2 polymorphisms with androgen levels is also controversial. Hsing et al. (18) found that of all these polymorphisms, only the L allele had a statistically significant relationship with higher testosterone and lower 5-androstane-3,17ß-diol glucuronide levels, but was not associated with apparent differences in DHT, estradiol, or steroid hormone binding globulin levels. A more marginal effect of the TA dinucleotide repeat polymorphism on DHT levels was also claimed (18) . However, other investigators (33 , 34) found actually lower testosterone levels with L/L, and in 2 studies (13 , 33) , the V89L polymorphism was not significantly associated with the levels of androstanediol glucuronide. Even if SRD5A2 is an important enzyme in androgen biosynthesis and even if the identified polymorphisms regulate its activity under certain experimental circumstances (8, 9, 10, 11) , there is no conclusive evidence that hormone levels are eventually affected in the serum, or more importantly, in the prostate tissue. Moreover, the exact role of androgens in the pathogenesis of prostate cancer has been a contentious issue (1 , 35 , 36) , so serum hormone levels may not provide definitive proof for the presence or not of genetic predisposition to prostate cancer. Polymorphisms in genes coding for other enzymes of the androgen biosynthesis and metabolism pathway have also been postulated as prostate cancer determinants (2) , but associations may also be refuted on scrutiny of the available evidence (37) .

Postulated genetic associations for prostate cancer need to be carefully validated across several studies, because early and small genetic association studies may come up with spurious findings (38, 39, 40) . Furthermore, genetic associations for such a multigenetic disease are likely to have relatively small ORs that would require large sample sizes to clarify. Some other limitations of this meta-analysis should be acknowledged. First, some nondifferential misclassification bias is possible. The majority of the considered studies could not exclude latent prostate cancer cases in the control group, and some controls may have developed prostate cancer during the subsequent years. However, the lifelong risk of prostate cancer among Americans is 16% (41) , so the OR dilution would probably be small. Furthermore, control groups included a large, often unknown proportion of subjects with BPH. BPH may be also androgen-dependent and affected by these same polymorphisms. However, one would then refer to a genetic factor conferring risk for prostate enlargement rather than cancer per se, a hypothesis with completely different connotations. Two (42 , 43) of 3 studies (34 , 42 , 43) to date do not support this hypothesis. Finally, the meta-analysis did not address familial prostate cancer, i.e., the hereditary forms where several members of the same family may be affected. One study (21) has found no association between A49T and familial prostate cancer. Moreover, such hereditary forms account for a very small portion of prostate cancer (31) and, thus, even strong genetic associations would have a limited impact on the incidence of prostate cancer at the population level.

	Acknowledgments

 
We thank Drs. Alain Latil and Nina Mononen for providing additional data and clarifications on their studies.

	Footnotes

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom requests for reprints should be addressed, at Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina 45110, Greece. Phone: 3026510-97807; Fax: 3026510-97867l E-mail: jioannid{at}cc.uoi.gr

² The abbreviations used are: DHT, dihydrotestosterone; BPH, benign prostatic hyperplasia; OR, odds ratio; CI, confidence interval.

Received 1/17/03; revised 3/21/03; accepted 4/ 1/03.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Gann P. H., Hennekens C. H., Ma J., Longcope C., Stampfer M. J. Prospective study of sex hormone levels and risk of prostate cancer. J. Natl. Cancer. Inst., 88: 1118-1126, 1996.[Abstract/Free Full Text]
2. Makridakis N. M., Reichardt J. K. Molecular epidemiology of hormone-metabolic loci in prostate cancer. Epidemiol. Rev., 23: 24-29, 2001.[Free Full Text]
3. Thigpen A. E., Davis D. L., Milatovich A., Mendonca B. B., Imperato McGinley J., Griffin J. E., Francke U., Wilson J. D., Russell D. W. Molecular genetics of steroid 5-reductase 2 deficiency. J. Clin. Investig., 90: 799-809, 1992.
4. Thigpen A. E., Silver R. I., Guileyardo J. M., Casey M. L., McConnell J. D., Russell D. W. Tissue distribution and ontogeny of steroid 5 -reductase isozyme expression. J. Clin. Investig., 92: 903-910, 1993.
5. Wilbert D. M., Griffin J. E., Wilson J. D. Characterization of the cytosol androgen receptor of the human prostate. J. Clin. Endocrinol. Metab., 56: 113-120, 1983.[Abstract]
6. Ross R. K., Bernstein L., Lobo R. A., Shimizu F. Z., Stanczyk F. Z., Pike M. C., Henderson B. E. 5-Reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet, 339: 887-889, 1992.[Medline]
7. Wu A. H., Whittemore A. S., Kolonel L. N., John E. M., Gallagher R. P., West D. W., Hankin J., The C. Z., Dreon D. M., Paffenbarger R. S., Jr. Serum androgens and sex-hormone binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol. Biomark. Prev., 4: 735-741, 1995.[Abstract]
8. Reichardt J. K., Makridakis N., Henderson B. E., Yu M. C., Pike M. C., Ross R. K. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res., 55: 3973-3975, 1995.[Abstract/Free Full Text]
9. Makridakis N., Ross R. K., Pike M. C., Chang P. L., Stanczyk F. Z., Kolonel L. N., Shi C. Y., Yu M. C., Henderson B. E., Reichardt J. K. A prevalent missense substitution that modulates activity of prostatic steroid 5-reductase. Cancer Res., 57: 1020-1022, 1997.[Abstract/Free Full Text]
10. Makridakis N. M., Ross R. K., Pike M. C., Crocitto L. E., Kolonel L. N., Pearce C. L., Henderson B. E., Reichardt J. K. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet, 354: 975-978, 1999.[Medline]
11. Davis D. L., Russell D. W. Unusual length polymorphism in human steroid 5--reductase type 2 gene (SRD5A2). Hum. Mol. Genet., 2: 820 1993.[Free Full Text]
12. Nam R. K., Toi A., Vesprini D., Ho M., Chu W., Harvie S., Sweet J., Trachtenberg J., Jewett M. A., Narod S. A. V89L polymorphism of type-2, 5- reductase enzyme gene predicts prostate cancer presence and progression. Urology, 57: 199-205, 2001.[Medline]
13. Febbo P. G., Kantoff P. W., Platz E. A., Casey D., Batter S., Giovannucci E., Hennekens C. H., Stampfer M. J. The V89L polymorphism in the 5-reductase type 2 gene and risk of prostate cancer. Cancer Res., 59: 5878-5881, 1999.[Abstract/Free Full Text]
14. Pearce C. L., Makridakis N. M., Ross R. K., Pike M., Kolonel L. N., Henderson B. E., Reichardt J. K. V. Steroid 5- reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study. Cancer Epidemiol. Biomark. Prev., 11: 417-418, 2002.[Free Full Text]
15. Lunn R. M., Bell D. A., Mohler J. L., Taylor J. A. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis (Lond.), 20: 1727-1731, 1999.[Abstract/Free Full Text]
16. Yamada Y., Watanabe M., Murata M., Yamanaka M., Kubota Y., Ito H., Katoh T., Kawamura J., Yatani R., Shiraishi T. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP-17) and steroid 5-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int. J. Cancer, 92: 683-686, 2001.[Medline]
17. Latil A. G., Azzouzi R., Cancel G. S., Guillaume E. C., Cochan-Priollet B., Berthon P. L., Cussenot O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer (Phila.), 92: 1130-1137, 2001.[Medline]
18. Hsing A. W., Chen C., Chokkalingam A. P., Gao Y. T., Dightman D. A., Nguyen H. T., Deng J., Cheng J., Sesterhenn I. A., Mostofi K., Stanczyk F. Z., Reichardt J. K. V. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol. Biomark. Prev., 10: 1077-1082, 2001.[Abstract/Free Full Text]
19. Soderstrom T., Wadelius M., Andersson S. O., Johansson J. E., Johansson S., Granath F., Rane A. 5-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics, 12: 307-312, 2002.[Medline]
20. Margiotti K., Sangiuolo F., De Luca A., Froio F., Pearce C. L., Ricci-Barbini V., Micali F., Bonafe M., Franceschi C., Dallapiccola B., Novelli G., Reichardt J. K. V. Evidence for an association between the SRD5A2 (type II steroid 5-reductase) locus and prostate cancer in Italian patients. Dis. Markers, 16: 147-150, 2000.[Medline]
21. Mononen N., Ikonen T., Syrjakoski K., Matikainen M., Schleutker J., Tammela T. L. J., Koivisto P. A., Kallioniemi O. P. A missense substitution A49T in the steroid 5--reductase gene (SRD5A2) is not associated with prostate cancer in Finland. Br. J. Cancer, 84: 1344-1347, 2001.[Medline]
22. Kantoff P. W., Febbo P. G., Giovannucci E., Krithivas K., Dahl D. M., Chang G., Hennekens C. H., Brown M., Stampfer M. J. A polymorphism of the 5 -reductase gene and its association with prostate cancer: a case-control analysis. Cancer Epidemiol. Biomark. Prev., 6: 189-192, 1997.[Abstract]
23. Lau J., Ioannidis J. P., Schmid C. H. Quantitative synthesis in systematic reviews. Ann. Intern. Med., 127: 820-826, 1997.[Abstract/Free Full Text]
24. Lau J., Antman E. M., Jimenez-Silva J., Kupelnick B., Mosteller F., Chalmers T. C. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N. Engl. J. Med., 327: 248-254, 1992.[Abstract]
25. Ioannidis J. P., Contopoulos-Ioannidis D. G., Lau J. Recursive cumulative meta-analysis: a diagnostic for the evolution of total randomized evidence from group and individual patient data. J. Clin. Epidemiol., 52: 281-291, 1999.[Medline]
26. Ioannidis J. P., Lau J. Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses. Proc. Natl. Acad. Sci. USA, 98: 831-836, 2001.[Abstract/Free Full Text]
27. Begg C. B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics, 50: 1088-1101, 1994.[Medline]
28. Shibata A., Garcia M. I., Cheng I., Stamey T. A., McNeal J. E., Brooks J. D., Henderson S., Yemoto C. E., Peehl D. M. Polymorphisms in the androgen receptor and type II 5 -reductase genes and prostate cancer prognosis. Prostate, 52: 269-278, 2002.[Medline]
29. Jaffe J. M., Malkowicz S. B., Walker A. H., MacBride S., Peschel R., Tomaszewski J., Van Arsdalen K., Wein A. J., Rebbeck T. R. Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res., 60: 1626-1630, 2000.[Abstract/Free Full Text]
30. Ostrander E. A., Stanford J. L. Genetics of prostate cancer: too many loci, too few genes. Am. J. Hum. Genet., 67: 1367-1375, 2000.[Medline]
31. Stanford J. L., Ostrander E. A. Familial prostate cancer. Epidemiol. Rev., 23: 19-23, 2001.[Free Full Text]
32. Ruijter E., van de Kaa C., Miller G., Ruiter D., Debruyne F., Schalken J. Molecular genetics and epidemiology of prostate carcinoma. Endocr. Rev., 20: 22-45, 1999.[Abstract/Free Full Text]
33. Allen N. E., Forrest M. S., Key T. J. The association between polymorphisms in the CYP17 and 5-reductase (SRD5A2) genes and serum androgen concentration in men. Cancer Epidemiol. Biomark. Prev., 10: 185-189, 2001.[Abstract/Free Full Text]
34. Schatzl G., Madersbacher S., Gsur A., Preyer M., Haidinger G., Haitel A., Vutuc C., Micksche M., Marberger M. Association of polymorphisms within androgen receptor, 5-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men. Prostate, 52: 130-138, 2002.[Medline]
35. Hsing A. W. Hormones and prostate cancer: what’s next?. Epidemiol. Rev., 23: 42-58, 2001.[Free Full Text]
36. Vatten L. J., Ursin G., Ross R. K., Stanczyk F. Z., Lobo R. A., Harvei S., Jellum E. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol. Biomark. Prev., 6: 967-969, 1997.[Abstract]
37. Ntais C., Polycarpou A., Ioannidis J. P. A. Association of CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol. Biomark. Prev., 12: 120-126, 2003.[Abstract/Free Full Text]
38. Ioannidis J. P., Ntzani E. E., Trikalinos T. A., Contopoulos-Ioannidis D. G. Replication validity of genetic association studies. Nat. Genet., 29: 306-309, 2001.[Medline]
39. Ioannidis J. P., Trikalinos T. A., Ntzani E. E., Contopoulos-Ioannidis D. G. Genetic associations in big vs. small studies: an empirical evaluation. Lancet, 361: 567-571, 2003.[Medline]
40. Ioannidis J. P. Genetic associations: false or true?. Trends Mol. Med., 9: 135-138, 2003.[Medline]
41. Greenlee R. T., Hill-Harmon M. B., Murray T., Thun M. Cancer statistics, 2001. CA Cancer J. Clin., 51: 15-36, 2001.[Abstract/Free Full Text]
42. Shibata A., Stamey T. A., McNeal J. E., Cheng I., Peehl D. M. Genetic polymorphisms in the androgen receptor and type II 5 -reductase genes in prostate enlargement. J. Urol., 166: 1560-1564, 2001.[Medline]
43. Azzouzi A. R., Cochand-Priollet B., Mangin P., Fournier G., Berthon P., Latil A., Cussenot O. Impact of constitutional genetic variation in androgen/oestrogen-regulating genes on age-related changes in human prostate. Eur. J. Endocrinol., 147: 479-484, 2002.[Abstract]

This article has been cited by other articles:

				K. C. Torkko, A. van Bokhoven, P. Mai, J. Beuten, I. Balic, T. E. Byers, J. E. Hokanson, J. M. Norris, A. E. Baron, M. S. Lucia, et al. VDR and SRD5A2 Polymorphisms Combine to Increase Risk for Prostate Cancer in Both Non-Hispanic White and Hispanic White Men Clin. Cancer Res., May 15, 2008; 14(10): 3223 - 3229. [Abstract] [Full Text] [PDF]

				J. Beesley, S. J. Jordan, A. B. Spurdle, H. Song, S. J. Ramus, S. K. Kjaer, E. Hogdall, R. A. DiCioccio, V. McGuire, A. S. Whittemore, et al. Association Between Single-Nucleotide Polymorphisms in Hormone Metabolism and DNA Repair Genes and Epithelial Ovarian Cancer: Results from Two Australian Studies and an Additional Validation Set Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2557 - 2565. [Abstract] [Full Text] [PDF]

				T. A. Trikalinos, G. Salanti, M. J. Khoury, and J. P. A. Ioannidis Impact of Violations and Deviations in Hardy-Weinberg Equilibrium on Postulated Gene-Disease Associations Am. J. Epidemiol., February 15, 2006; 163(4): 300 - 309. [Abstract] [Full Text] [PDF]

				H. T. T. Thai, M. Kalbasi, K. Lagerstedt, L. Frisen, I. Kockum, and A. Nordenskjold The Valine Allele of the V89L Polymorphism in the 5-{alpha}-Reductase Gene Confers a Reduced Risk for Hypospadias J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6695 - 6698. [Abstract] [Full Text] [PDF]

				C. Ntais, A. Polycarpou, and J. P.A. Ioannidis Association of GSTM1, GSTT1, and GSTP1 Gene Polymorphisms with the Risk of Prostate Cancer: A Meta-analysis Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 176 - 181. [Abstract] [Full Text] [PDF]

				D. J. Schaid The complex genetic epidemiology of prostate cancer Hum. Mol. Genet., April 1, 2004; 13(90001): R103 - 121. [Abstract] [Full Text] [PDF]

				C. Ntais, A. Polycarpou, and J. P. A. Ioannidis Vitamin D Receptor Gene Polymorphisms and Risk of Prostate Cancer: A Meta-analysis Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1395 - 1402. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ntais, C. Articles by Ioannidis, J. P. A. Search for Related Content PubMed PubMed Citation Articles by Ntais, C. Articles by Ioannidis, J. P. A.